Margaret von Mehren

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +14

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · Journal of Clinical Oncology · 2003 · 2.3K citations

Medicine, Molecular Medicine, Oncology +17

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri, Peter Reichardt, Yoon‐Koo Kang et al. · The Lancet · 2012 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +8

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Oncology, Surgery +11

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu et al. · Journal of the National Comprehensive Cancer Network · 2010 · 1.2K citations

Medicine, Oncology, Pathology +17